HOME >> MEDICINE >> NEWS
Women treated more aggressively for hypertension, yet results similar to men

ORLANDO, FLA. -- Duke University Medical Center researchers have found an interesting paradox about gender differences in heart disease -- women have a greater burden of hypertension than their male counterparts and they receive more aggressive treatment for it, yet they obtain no better blood pressure control.

Since their study also found that the impact of hypertension on mortality or recurrent cardiac events was similar between men and women, the researchers believe there are great opportunities to improve medical therapy and outcomes in women.

Cardiologist Kristin Newby, M.D., of the Duke Clinical Research Institute, presented the results of her analysis today (Nov. 12, 2003) at the 76th annual scientific session of the American Heart Association.

Newby wanted to know how the prevalence and treatment of hypertension varied between the sexes in patients who came to the hospital with an acute coronary syndrome (ACS), which occurs when a patient arrives at the hospital with chest pain and physicians must determine whether or not the symptoms are due to unstable angina or signal a real heart attack.

"Hypertension afflicts more than one billion worldwide and has been proven to be an independent risk factor for death or further cardiac events after ACS," Newby explained. "There is little doubt that hypertensive women with ACS are at a higher unadjusted risk for death or heart attack, but when you statistically adjust for such factors as age, kidney function, diabetes or other heart problems, the risks turn out to be about the same. The difference in outcomes does not appear to be due totally to gender, but at least in part to these and other factors."

To answer that question, Newby consulted data gathered from two related international trials -- SYMPHONY and 2nd SYMPHONY (Sibrafabin vs. aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes). While these trials were designed to compare the e
'"/>

Contact: Richard Merritt
merri006@mc.duke.edu
919-684-4148
Duke University Medical Center
12-Nov-2003


Page: 1 2 3

Related medicine news :

1. The European Society of Cardiology launches Women at Heart
2. Women less likely to get quality heart attack care
3. Statement on the findings of the Womens Health Study
4. Women should be advised not to drink alcohol in pregnancy
5. Women with thyroid problem have lower risk of breast cancer
6. Women successfully treated to prevent preterm labor at low risk for recurrent episode
7. Womens heart risk underestimated by doctors, resulting in less preventive care than in men
8. Women, drinking to their health
9. Women want annual pap smears
10. Women In Government report on eliminating cervical cancer
11. Women need less morphine after hysterectomies with new treatment

Post Your Comments:
(Date:5/21/2013)... An attack on glioblastoma brain tumor cells that ... an early study to establish the proper dose level, ... developed at Duke and tested in an ongoing phase ... have an abundance of receptors that work like magnets ... cells. , The investigational therapy, known as PVSRIPO, ...
(Date:5/21/2013)... Adeptia, a leading provider of innovative cloud ... is the featured company in an impact report written ... “Adeptia Bets on Converged Cloud Integration and Process-Orchestration Suites,” ... products, pricing, customers and competition. , “For ... integration and process orchestration, especially when price, ease of ...
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) -- ... some of the changes brought about by the disorder ... New research has found that people with diabetes who ... risk of having a severe low blood sugar (hypoglycemia) ... people with diabetes who aren,t depressed. "Depression ...
(Date:5/21/2013)... Grapefruits have long been known for their ... how medical therapies like anti-cancer drugs are delivered ... researchers have uncovered how to create nanoparticles using ... how to use them as drug delivery vehicles. ... Ph.D., and their team today (May 21, 2013), ...
(Date:5/21/2013)... May 21, 2013 Benefit Express Services, ... medium, and small organizations, will be hosting a free ... team from Findley Davies. The presentation will focus on ... in compliance with new Health Care Reform Requirements. The ... employees. , “Benefit Express regularly hosts free educational ...
Breaking Medicine News(10 mins):Health News:Poliovirus vaccine trial shows early promise for recurrent glioblastoma 2Health News:Adeptia Featured in Recent 451 Research Impact Report 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 3Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2Health News:Benefit Express to Host Workplace Wellness Webinar 2
(Date:5/21/2013)...  Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...
(Date:5/21/2013)... 2013 Abaxis, Inc. (NasdaqGS: ABAX), a medical ... that Martin Mulroy , chief commercial ... & Veterinary Conference on Wednesday, May 29, 2013 at ... Le Parker Meridien Hotel in New York ... Abaxis develops, manufactures, markets and sells portable blood analysis ...
(Date:5/21/2013)... 2013  BioRestorative Therapies, Inc. ("BRT" or the "Company") ... developing stem cell based therapies for various personal applications, ... President and CEO, will be presenting at the Marcum ... held on Thursday, May 30, 2013 at the Grand ... New York City.  Mr. Weinreb,s presentation will take place ...
Breaking Medicine Technology:Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
Cached News: